• Angiotensin II Receptor Blockade Enhances Immunotherapy in C

  2026-07-07

  This study identifies AGTR1 as a biomarker and actionable target in armored and cold tumors, which are resistant to immune checkpoint blockade. By using angiotensin II receptor antagonists to modulate the tumor microenvironment, the research demonstrates improved immune infiltration and therapeutic response, offering a new avenue for combination cancer therapies.

• Bestatin Hydrochloride: Mechanistic Insight & Translational

  2026-07-07

  This article delivers a thought-leadership perspective on Bestatin hydrochloride (Ubenimex), integrating mechanistic depth with strategic guidance for translational researchers. It unpacks the inhibitor’s dual impact on aminopeptidase N/B, explores validated protocols, competitive advantages, and the broader clinical implications for cancer and neurovascular research. Drawing upon pivotal literature, including cross-domain neurobiology evidence, this piece transcends traditional product summaries—equipping researchers to translate bench findings into meaningful preclinical and clinical advancements.

• Mitochondrial NAD+ Deficiency Drives Aortic Aneurysm via Col

  2026-07-06

  This study reveals mitochondrial NAD+ deficiency in vascular smooth muscle cells as a direct cause of thoracic and abdominal aortic aneurysm, mediated by impaired collagen III turnover and compromised proline biosynthesis. These findings identify new molecular mechanisms underlying aortic disease and highlight potential therapeutic targets for vascular remodeling.

• JC-1: Precision Mitochondrial Membrane Potential Assays Unlo

  2026-07-06

  JC-1 stands out as the gold-standard fluorescent probe for mitochondrial membrane potential, enabling sensitive detection of apoptosis and mitochondrial dysfunction in live cells. This article delivers actionable workflows, troubleshooting strategies, and insight into leveraging JC-1 for cutting-edge cellular bioenergetics and cancer research applications.

• Mechanisms of Cell Death in Heart Disease: Regulated Apoptos

  2026-07-05

  This article examines the pivotal 2012 review on cell death mechanisms in heart disease, highlighting how both apoptosis and regulated necrosis contribute to cardiac pathology. The findings underscore the interconnectedness of cell death pathways and point to the potential of pharmacological inhibitors, such as calpain inhibitors, in modulating disease progression.

• Bestatin Hydrochloride: Mechanism-Driven Strategies for Tran

  2026-07-04

  This thought-leadership article explores the mechanistic rationale, experimental validation, and translational significance of Bestatin hydrochloride (Ubenimex) as a dual aminopeptidase N/B inhibitor. By integrating evidence from landmark neuroscience and cancer research, we provide strategic guidance for leveraging Bestatin hydrochloride in advanced angiogenesis and tumor invasion models, while highlighting APExBIO's role in supplying rigorously characterized reagents. The piece moves beyond conventional product briefs, offering workflow-anchored insights and a critical perspective on the evolving landscape of exopeptidase inhibition in translational science.

• Gastrin I in Human Organoid Models for Gastric Acid Pathway

  2026-07-03

  Harnessing human Gastrin I peptide in advanced organoid and cell-based systems unlocks precise modeling of the gastric acid secretion pathway and CCK2 receptor signaling. This article details state-of-the-art workflows, protocol enhancements, and troubleshooting tips to maximize the utility of APExBIO’s high-purity Gastrin I (human) in gastrointestinal physiology and disorder research.

• Psora 4: Advanced Kv1.3 Blocker for High-Fidelity T Cell Ass

  2026-07-03

  Psora 4 is a highly selective Kv1.3 blocker enabling precise modulation of effector memory T cells, with workflow reproducibility for both in vitro and in vivo immune research. Its unique inhibition kinetics and low toxicity profile make it the compound of choice for advanced immunomodulation and kidney inflammation models.

• Fosinopril Sodium (SKU A4079): Reliable ACE Inhibition in La

  2026-07-02

  This article delivers evidence-based guidance for using Fosinopril sodium (SKU A4079) in cell viability, proliferation, and cytotoxicity assays. Drawing on validated protocols and literature, it addresses common experimental obstacles and demonstrates how APExBIO’s Fosinopril sodium optimizes reproducibility, data interpretation, and workflow efficiency for hypertension and cardiovascular disease models.

• AMPK-PGC-1α-SOD Axis Shields Cardiac Cells from Doxorubicin

  2026-07-02

  This study reveals that hydroethanolic extracts of Cirsium setidens protect against doxorubicin-induced cardiotoxicity by activating the AMPK-PGC-1α-NRF1 pathway and enhancing mitochondrial antioxidant defenses. The findings highlight a targeted approach to reducing cardiac side effects in chemotherapy, with implications for metabolic and cardiovascular disease research.

• BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Guidan

  2026-07-01

  BFH772 is a highly selective VEGFR2 inhibitor designed for targeted suppression of VEGFR2-mediated angiogenesis in research workflows, especially tumor model studies. It should be used where high kinase selectivity and compatibility with organic solvents are required, and is not suitable for protocols that need water solubility or broad-spectrum kinase inhibition.

• Ultrasonically Powered Implantable TTF: Advancing Localized

  2026-07-01

  This study introduces a battery-free, ultrasonically powered implantable Tumor Treating Field (i-TTF) system leveraging BaTiO3 pyramid-shaped nanoparticle receivers for efficient, localized electric field delivery in glioblastoma treatment. The work demonstrates improved power transfer, field focality, and in vitro/in vivo anti-proliferative efficacy, addressing major limitations of current scalp-array TTF approaches.

• Aminopeptidase Inhibition Modulates Angiotensin Activity in

  2026-06-30

  This study demonstrates that Bestatin hydrochloride (Ubenimex), an inhibitor of aminopeptidase B, enhances angiotensin II and III-evoked neuronal activity in rat brain, supporting a model where angiotensin II requires conversion to angiotensin III for central activation. These findings clarify enzymatic regulation of neuropeptide signaling and inform the use of aminopeptidase inhibitors in neurophysiological and translational research.

• Sphingosine-1-phosphate (S1P): Reliable Solutions for Cell A

  2026-06-30

  This article addresses common laboratory challenges in cell viability and apoptosis assays, demonstrating how Sphingosine-1-phosphate (SKU B6707) from APExBIO offers reliable, data-backed solutions. Scenario-driven Q&A blocks guide researchers through mechanism, protocol optimization, data interpretation, and vendor selection, linking evidence to practical workflows.

• TBXA2R-ERM Signaling Drives Metastasis in Triple-Negative Br

  2026-06-29

  This study uncovers how the thromboxane A2 receptor (TBXA2R), a GPCR, activates ERM proteins to promote cell motility, invasion, and metastatic colonization in triple-negative breast cancer (TNBC) cells. By elucidating this signaling axis, the findings offer new mechanistic targets for anti-metastatic interventions and expand our understanding of GPCR-driven cancer progression.

15400 records 1/1027 page Next 12345 下5页 Last page